

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	F1	LING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/049,702	04/15/2002		Camilo Anthony Leo Selwyn Colaco	8830-24	7592
23973	7590	12/03/2003		EXAMINER	
DRINKER			SHAHNAN SHAH, KHATOL S		
ONE LOGAN SQUARE 18TH AND CHERRY STREETS				ART UNIT	PAPER NUMBER
PHILADELPHIA, PA 19103-6996				1645	

DATE MAILED: 12/03/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)					
Office Action Summary	10/049,702	COLACO, CAMILO ANTHONY LEO SELWYN					
Office Action Summary	Examiner	Art Unit					
	Khatol S Shahnan-Shah	1645					
Th MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply - If NO period for reply is specified above, the maximum statutory period w - Failure to reply within the set or extended period for reply will, by statute, - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
1) Responsive to communication(s) filed on	<u></u> .						
2a) ☐ This action is FINAL . 2b) ☐ This	action is non-final.						
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disp sition of Claims							
4) ⊠ Claim(s) <u>1-13</u> is/are pending in the application. 4a) Of the above claim(s) is/are withdraw 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-13</u> are subject to restriction and/or expressions.	wn from consideration.						
Application Papers							
9) The specification is objected to by the Examiner.							
10)☐ The drawing(s) filed on is/are: a)☐ accepted or b)☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. §§ 119 and 120							
a) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the priority application from the International Bureau * See the attached detailed Office action for a list 13) Acknowledgment is made of a claim for domestic since a specific reference was included in the first 37 CFR 1.78. a) The translation of the foreign language pro 14) Acknowledgment is made of a claim for domestic reference was included in the first sentence of the	s have been received. s have been received in Application ity documents have been received (PCT Rule 17.2(a)). of the certified copies not received c priority under 35 U.S.C. § 119(a) st sentence of the specification or visional application has been received c priority under 35 U.S.C. §§ 120	on No ed in this National Stage d. e) (to a provisional application) in an Application Data Sheet. eived. and/or 121 since a specific					
Attachment(s)							
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) Information Disclosure Statement(s) (PTO-1449) Paper No(s) 	5) Notice of Informal P	(PTO-413) Paper No(s) atent Application (PTO-152)					

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. 121:
 - I. Claims 1-7 are, drawn to a method of producing a vaccine, classified in class 435, subclass 7.2
 - II. Claims 8-11 are, drawn to a vaccine, classified in class 424, subclass 234.1
 - III. Claims 12-13 are, drawn to a method of treating an animal, classified in class 424, subclass 193.1.
- 2. The inventions are distinct, each from the other because of the following reasons:

 Groups I-III are distinct because claims of group I are drawn to a product. Those of groups II-III are drawn to distinct methods.

Inventions II and III are drawn to different methods. The inventions are shown to be distinct because they are drawn to distinct methods, which differ in method objectives, method steps, reagents and material used.

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the vaccine of group II can be produced by the inactivating the organisms by formalin.

Inventions I and III are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product

Art Unit: 1645

as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case a different vaccine can be used to treat said animal.

- 3. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper. The several inventions above are independent and distinct, each from the other for the reasons stated. They have also acquired a separate status in the art as a separate subject for inventive effect and requires independent searches. The search of each of the above inventions is not co-extensive particularly with regard to the literature search. Further, a reference which would anticipate the invention of one group would not necessarily anticipate or make obvious the any of the other groups.
- 4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Conclusion

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Khatol Shahnan-Shah whose telephone number is (703) 308-8896. The examiner can normally be reached on 7:30 AM - 4 PM from Monday through Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Lynette F Smith, can be reached on (703) 308-3909. The fax phone number for the organization where this application or proceeding is assigned to is (703) 305-3014.

Art Unit: 1645

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Khatol Shahnan-Shah, BS, Pharm, MS

Biotechnology Patent Examiner

Art Unit 1645

November 28, 2003

RODNEY P SWARTZ, PH.D PRIMARY EXAMINER